Article

Particle Size, Surface Area, and Amorphous Content as Predictors of Solubility and Bioavailability for Five Commercial Sources of Ferric Orthophosphate in Ready-To-Eat Cereal

Robin S. Dickmann 1,*,†, Gale M. Strasburg 2,‡, Dale R. Romsos 2,†, Lori A. Wilson 1, Grace H. Lai 1 and Hsimin Huang 1

1 Kellogg Company, W.K. Kellogg Institute for Food and Nutrition Research, Battle Creek, 2 Hamblin Avenue, Battle Creek, MI 49015, USA; lori.wilson@kellogg.com (L.A.W.); gracehlai@hotmail.com (G.H.L.); hsimin.huang@kellogg.com (H.H.)
2 Department of Food Science and Human Nutrition, Michigan State University, 469 Wilson Road, East Lansing, MI 48824, USA; stragale@anr.msu.edu (G.M.S.); dromsos@anr.msu.edu (D.R.R.)
* Correspondence: rsdmalone@gmail.com; Tel.: +1-231-335-5021; Fax: +1-517-432-0753
† These authors contributed equally to this work.

Received: 22 November 2015; Accepted: 23 February 2016; Published: 1 March 2016

Abstract: Ferric orthophosphate (FePO₄) has had limited use as an iron fortificant in ready-to-eat (RTE) cereal because of its variable bioavailability, the mechanism of which is poorly understood. Even though FePO₄ has desirable sensory properties as compared to other affordable iron fortificants, few published studies have well-characterized its physicochemical properties. Semi-crystalline materials such as FePO₄ have varying degrees of molecular disorder, referred to as amorphous content, which is hypothesized to be an important factor in bioavailability. The objective of this study was to systematically measure the physicochemical factors of particle size, surface area, amorphous content, and solubility underlying the variation in FePO₄ bioavailability. Five commercial FePO₄ sources and ferrous sulfate were added to individual batches of RTE cereal. The relative bioavailability value (RBV) of each iron source, determined using the AOAC Rat Hemoglobin Repletion Bioassay, ranged from 51% to 99% (p < 0.05), which is higher than typically reported. Solubility in dilute HCl accurately predicted RBV (R² = 0.93, p = 0.008). Amorphous content measured by Dynamic Vapor Sorption ranged from 1.7% to 23.8% and was a better determinant of solubility (R² = 0.91; p = 0.0002) than surface area (R² = 0.83; p = 0.002) and median particle size (R² = 0.59; p = 0.12). The results indicate that while solubility of FePO₄ is highly predictive of RBV, solubility, in turn, is strongly linked to amorphous content and surface area. This information may prove useful for the production of FePO₄ with the desired RBV.

Keywords: ferric orthophosphate; reduced iron; bioavailability; solubility; particle size; surface area; amorphous content; X-ray diffraction; dynamic vapor sorption; physicochemical properties

1. Introduction

Fortifying foods with inorganic iron remains a challenge. Many forms of inorganic iron can be used to fortify food but few forms provide the desired combination of bioavailability and product stability. Freely soluble iron forms such as ferrous sulfate have the highest bioavailability since iron and must be solubilized in gastric juice before it can be absorbed by the body [1–4]. However, soluble iron is also a pro-oxidant, has a metallic off-taste and reacts with many food components causing negative organoleptic changes and shortened shelf life [5–7]. As a result, less soluble and thus less reactive forms of iron are often chosen for food applications. To be absorbed by the small intestine, some portion
of the dietary iron must first dissolve in stomach acid [4]. The solubilities of the various elemental or compound forms of iron depend on their method of manufacture which, in turn, may result in a wide range of bioavailabilities even for the same form of iron [3,5,7–9]. Concerns were raised by the scientific community at the Monterrey Workshop in 2000 about the efficacy of elemental iron due to its variable and often poor bioavailability reported in the literature [2]. Nevertheless, elemental iron is the most widely used iron fortificant in cereal and cereal products due to its low cost and fewer stability and organoleptic problems [10]. Results of the SUSTAIN Task Force on Iron Powders collaborative study found the RBVs of commercial elemental iron powders to vary considerably (RBV 21%–64%, relative to ferrous sulfate, defined as RBV 100%) [10,11]. Commonly used, affordable forms of iron with excellent bioavailability include for example, ferrous sulfate and ferrous fumarate [1,3,12]. However, these highly bioavailable forms of iron pose sensory and stability issues due to the accompanying increase in iron solubility within the food matrix.

Ferric orthophosphate (FePO$_4$) is preferred over elemental iron for liquid products, light-colored food, and oxidatively sensitive food applications because of its low density, light color, good stability, and non-metallic flavor. However, historically FePO$_4$ is thought to have little nutritional value and this has limited its use as a fortificant [1,7,13,14]. According to a Mintel Global New Product Database (GNPD) search from January 1996–January 2016, there were 2121 food and beverage products including snack/cereal/energy bars, hot and cold cereals, enriched rice and meal replacement drinks containing FePO$_4$ marketed globally. This compares to over 18,900 food and beverage products marketed during the same period that were fortified with all types of iron [15]. There is limited information in the literature about the physicochemical properties of FePO$_4$ and their influence on bioavailability; the paucity of information preclude its widespread use as a food fortificant. Therefore, the objectives of this study were to characterize the physicochemical properties of five sources of commercially available, food-grade FePO$_4$ to determine which properties have the greatest influence on in vivo relative bioavailability (RBV). Solubility, particle size, surface area, and amorphous content of each of the FePO$_4$ powders were quantified and correlated with RBV.

2. Experimental Section

2.1. Iron Sources

FePO$_4$ Sources 1, 2, 3, and 4 were obtained from Budenheim Chemische Fabrik (Mainz, Germany) and had product numbers 53–80, 53–81, 53–82, and 53–85, respectively. FePO$_4$ Source 5 was obtained from Madison Chemicals, Inc. (Madison Township, NJ, USA). By supplier specification, all FePO$_4$ sources were food grade and >99% pure; pH ranged from 3 to 5. Standard ferrous sulfate heptahydrate (Source 6) was purchased from Mallinckrodt Baker, Inc. (Phillipsburg, NJ, USA). The color and texture of the FePO$_4$ powders varied. Source 1 was a dull-yellow, fine powder that clung to surfaces, Sources 2, 3, and 4 were beige to off-white powders with poor flow properties, and Source 5 was a pinkish-white, talc-like powder with good flowability. There were also distinct differences in organoleptic characteristics among the FePO$_4$ powders, with Source 1 exhibiting an objectionable strong metallic taste and odor and Source 5 exhibiting a desirable bland flavor. Supplier information stated that the products varied in particle size and therefore solubility in water and dilute mineral acids.

Physical property measurements were made on the same lots of FePO$_4$ that were used for the AOAC Rat Hemoglobin Repletion Study, identified as lot 1 for Source 1–5. Additional production lots were available for Source 1 (one lot), Source 2 (one lot, particle size and surface area only), and Source 3 (two lots) and analyzed to indicate lot-to-lot process variation.

2.2. AOAC Rat Hemoglobin Repletion Bioassay

Relative bioavailability value (RBV) of the FePO$_4$ was determined using the AOAC Rat Hemoglobin Repletion Bioassay/slope ratio method [16]. Iron-deficient rats were given repletion diets fortified with graded quantities of FePO$_4$ powders, ferrous sulfate, or a no-added-iron diet. The study
2.2.1. Animals

Male Hsd: Sprague Dawley® SD® rats were procured at 21 days of age from Harlan Sprague Dawley, Inc. (Madison, WI, USA). They were single-housed in wire-bottomed, stainless steel cages and subjected to a 12-h light/12-h dark cycle. Upon arrival, the rats were immediately fed ad libitum the iron-depletion diet for 15 days. Blood was collected from the jugular vein at the end of the iron-depletion period and analyzed for hemoglobin concentration. The animals were then randomly assigned to test diet groups at 36 days of age with 10 animals per group. The animals were fed ad libitum their respective iron-repletion diets for two weeks from clear glass jars. Fresh food was offered on day 1 and day 8. Individual animal body weight data were recorded on days 1, 8, and 15, and individual food consumption data were recorded weekly during the test period. The animals were bled on day 15 and the final hemoglobin levels determined.

2.2.2. Animal Iron-Depletion and Repletion Diets

The iron-depletion animal diet, Diet TD 0396, was purchased from Harlan Teklad (Madison, WI, USA), and included 35.0 g/kg iron-deficient mineral mix (TD81062) and 10.0 g/kg vitamin mix AIN-76A (TD40077). The animals also received ad libitum a deionized water source (analyzed for iron content).

Seven batches of RTE-cereal were produced and used to make the rat iron repletion diets. Five batches were made with the five respective FePO₄ sources, a sixth batch was made with ferrous sulfate, and a seventh batch without any added iron. Ingredients in the RTE-cereal included whole corn grits, malted barley flavor, corn syrup, sugar, salt, and the following added vitamins per 30 g serving of finished product: A (500 IU), C (6 mg), D (40 IU), B-12 (1.5 µg), B-1 (0.4 mg), B-2 (0.4 mg), B-6 (0.5 mg), niacin (5 mg), and folate (0.1 mg). Each iron source was added to a 90-kg batch of corn cereal before processing to provide 8 mg of iron per 30 g cereal. The cereal, iron sources, and other added ingredients underwent a pressurized batch-cooking process (Kellogg Company pilot plant, Battle Creek, MI, USA) and then were tempered, flaked, and toasted. After processing, the diets were prepared in 1-kg batches to contain 60% (600 g) iron-depletion animal diet and 40% (400 g) RTE-cereal. The RTE-cereal made with and without added iron was proportioned to formulate target doses of 0, 6, 12, 24, or 48 mg of each test iron source per kg rat iron-repletion diet. The iron content of each iron source and test diet was measured using Inductively Coupled Plasma (ICP) mass spectrometry [17].

2.3. In Vitro Solubility

The method used for determination of the solubility of the iron sources was based on the method of Shah and others[6] and later modified by Forbes and others [18]. To decrease assay variability, the method was further modified to incorporate the dissolution apparatus and precisely controlled temperature, mixing, and filtering conditions as described in the United States Pharmacopeial Convention (USPC) 2006 Official Method for Dietary Supplements, #2040 Disintegration and Dissolution of Dietary Vitamin and Mineral Supplements. Approximately 0.29 mg total iron was analyzed per sample (ca. 1.12 g FePO₄). Samples were dissolved in 450 mL (2–3 mg iron/mL) of one of the three following standardized HCl (Fisher Scientific, Pittsburg, PA, USA) solutions: 0.02 N, 0.05 N, or 0.10 N. The amount of dissolved iron was determined by ICP mass spectrometry and expressed as a percentage of iron dissolved (weight basis) [17].

2.4. Particle Size Distributions

The particle size distributions were determined by Particle Technology Labs, Ltd. (Method MM324.01) (Downers Grove, IL, USA) using a Malvern Mastersizer 2000 Laser Diffraction. Four 12-s analyses were made at one-minute intervals, and results reported as the average of the four analyses...
for each sample. The analysis was repeated six times for each lot of FePO₄. The following four mean volume statistics were calculated: mean particle size diameter (µm); and three cumulative percent statistics D₁₀, D₅₀ (median), and D₉₀ that are the percentages of the total sample less than the measured particle size (µm). The refractive indices were determined for the FePO₄ samples by the Becke Line Test for the sodium line (589 nm) using the microscopic emersion method.

2.5. Surface Area

Surface area measurements were made by Particle Technology, Ltd. using a five-point Brunauer, Emmett, and Teller (B.E.T.) surface area analysis performed on a Quantachrome Autosorb-AS-1 Static-Pressure instrument (Method AU225.01). Samples of 2.2–2.6 g were weighed to four decimal places and prepared for analysis by out-gassing under a helium purge at 25 °C for 16 h until the samples were thoroughly dry and free of surface contamination. Analysis was carried out using nitrogen as the adsorbate gas (maintained at a temperature of 77.4 °K) over the following five B.E.T. points: 0.10, 0.15, 0.20, 0.25, and 0.30. The analysis was repeated six times for each lot of FePO₄.

2.6. Amorphous Content

The microstructures of the FePO₄ sources 1–5 were examined by polarized light microscopy using white light through crossed polarizers and first order red compensation in a light red background. FePO₄ crystals are anisotropic (non-uniform) with two refractive indices (birefringence) when plane polarized light is passed through the material. The birefringent crystals appear brightly colored while the amorphous FePO₄, lacking the molecular order and pattern of crystals, is not birefringent and appears clear.

Powder X-ray diffraction was performed by McCrone Associates, Inc. (Westmont, IL, USA) to profile the crystal structures of the FePO₄ sources. The instrument used was a Siemens D5000 powder diffractometer. The samples were prepared as random powder specimens by loading into plastic dishes. The samples were X-rayed from 2 to 50 degrees 2-theta using copper radiation, an accelerating voltage of 40 kV/30 mA, a step size of 0.05 degrees, and a data acquisition time of 2.0 s per step, with the sample spinning.

The amorphous content of the FePO₄ sources was determined by measuring the moisture uptake of the material by dynamic vapor sorption (DVS). The DVS moisture uptake method was developed by J.Y.Y. Heng and D.R. Williams (Department of Chemical Engineering, Imperial College, London, UK). A DVS-1 instrument (Surface Measurement Systems UK Ltd., Alperton London, UK) equipped with a Cahn D-100 microbalance (sensitivity 0.1 µg) was used to produce isotherms for each of the FePO₄ sources. Isotherm analyses were conducted by weighing ca. 50 mg of FePO₄ into the microbalance module and pre-conditioning at 0% relative humidity (RH) for 300 min. Following pre-conditioning, the relative humidity (RH) was incrementally increased on average every 60 min as follows: 0, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90% RH and then reversed to complete one sorption/desorption isotherm cycle over approximately 2000 min. A minimum of two consecutive isotherm cycles were conducted on each source of FePO₄ to determine if the samples displayed moisture induced phase changes and to determine optimum cycle-time. Samples were held at each change in humidity until the sample weight (moisture uptake) stabilized.

A 100% amorphous FePO₄ standard was prepared from Source 4. Source 4 was chosen because it was highly amorphous by X-ray diffraction and polarized light microscopy. The standard was prepared by completely dissolving FePO₄ Source 4 in 0.10N HCl and spray drying (Buchi B-290 apparatus, Buchi, Oldham, UK) the material to form an amorphous powder. The amorphous content of each FePO₄ source (1–5) and the standard were measured by DVS using the same isotherm analysis parameters previously described. The amorphous FePO₄ standard material was extremely hygroscopic and mass equilibration was closely approximated but not fully reached above 10% RH during the 2000-min isotherm cycle-time. Therefore, estimations of amorphous content were made by a ratio comparison of the moisture uptake of each FePO₄ source to the 100% amorphous standard using the data at 10% RH.
2.7. Statistical Analysis

RBVs were based on the change in hemoglobin concentration (g/L) from the end of the iron-depletion period to the end of the iron-repletion period (day-15). Hemoglobin values from rats on FePO$_4$ test diets 1–5 were compared to that of the standard ferrous sulfate treatment (Diet 6) that was assigned an RBV of 100%. Linearity of the regression curves was determined separately for each diet and a multiple regression model was used to determine the slopes of the test and control iron sources. The RBVs were calculated using the following equation:

$$\% \text{RBV} = \frac{\text{Slope of the test diet (1–5)}}{\text{Slope of the standard diet (6)}} \times 100$$

The standard error was calculated using the equation:

$$\text{SE} = \sqrt{\frac{\text{SE}_k^2 + R^2 + \text{SE}_k^2}{n}}$$

where $q$ is the slope of the standard diet, and $p$ is the slope of the test diet. The standard errors of $p$ and $q$ are shown as $\text{SE}_p$ and $\text{SE}_q$. The relative bioavailability is $R$.

Solubility analyses were conducted in triplicate on Sources 1–5 while six replicates were performed for particle size and surface area measurements. A least squares analysis of variance was performed on the physical property data. Physical properties were considered a function of the source of the iron and therefore fixed effects, while lot was considered a random effect. Independent linear regression analyses at 95% confidence level were performed on particle size, surface area, and moisture uptake measurements versus solubility and RBV data. The log$_{10}$ surface area and log$_{10}$ solubility data were used to give a better fit to the data because of the rapid increase in these measurements with increasing amorphous content. Estimates of amorphous content (by DVS moisture uptake) were based on a minimum of two isotherm analyses per source of FePO$_4$.

3. Results

3.1. AOAC Rat Hemoglobin Repletion Bioassay

The iron content of the repletion diets and the change in hemoglobin data are shown in Table 1. Data from the ICP analysis of the iron content of the sources were used to calculate how much of each source to add to the repletion diets. The iron contents of FePO$_4$ ranged from 26.4% to 29.3% depending on the number of water molecules of hydration (Mean iron contents, $n = 2$: Source 1, 27.4%; Source 2, 28.4%; Source 3, 28.7%; Source 4, 28.4%; Source 5, 28.1%). All diets contained 4 mg of naturally occurring iron from the malted barley per kg of the cereal formulation. Thus, the endogenous iron added about 4 mg of iron to the total iron content of each diet (4 mg above the target iron dose).

| Test Iron and Hemoglobin Gain | 6 mg/kg | 12 mg/kg | 24 mg/kg |
|-----------------------------|--------|---------|---------|
| Diet 1, Source 1 (mg iron/kg diet) | 11 | 17 | 27 |
| Hemoglobin gain (g/L) | $-3 \pm 6$ | $16 \pm 6$ | $53 \pm 6$ |
| Diet 2, Source 2 (mg iron/kg diet) | 11 | 16 | 28 |
| Hemoglobin gain (g/L) | $-5 \pm 3$ | $6 \pm 5$ | $40 \pm 6$ |
| Diet 3, Source 3 (mg iron/kg diet) | 11 | 16 | 29 |
| Hemoglobin gain (g/L) | $-10 \pm 4$ | $-1 \pm 6$ | $22 \pm 9$ |
| Diet 4, Source 4 (mg iron/kg diet) | 10 | 16 | 28 |
| Hemoglobin gain (g/L) | $-5 \pm 4$ | $9 \pm 7$ | $40 \pm 5$ |
| Diet 5, Source 5 (mg iron/kg diet) | 10 | 14 | 25 |
| Hemoglobin gain (g/L) | $-10 \pm 3$ | $-3 \pm 5$ | $20 \pm 6$ |
| Diet 6, Source 6 ferrous sulfate (mg iron/kg diet) | 10 | 16 | 25 |
| Hemoglobin gain (g/L) | $-2 \pm 9$ | $22 \pm 11$ | $44 \pm 11$ |

* Mean ± SD of 10 animals per study group per FePO$_4$ Source tested; $^b$ Hemoglobin values at the zero dose level (no added FePO$_4$) were $-21 \pm 5$; $^c$ Diets 1–5, all dose levels ($n = 1$); Diet 6 standard ferrous sulfate: dose level 0 mg/kg ($n = 2$), dose levels 4 and 6 mg/kg ($n = 4$), dose level 24 mg/kg ($n = 5$).
A linearity test was performed on Diets 1–5 comparing the test iron content of each diet versus the change in hemoglobin in rats fed each diet during the repletion study. Significant lack-of-fit occurred at \( p \leq 0.05 \) when the highest test dose (i.e., 48 mg iron/kg diet; Diets 1–6 mean gain Hgb g/L: 69 ± 8; 56 ± 8; 33 ± 9; 64 ± 5; 43 ± 8; 62 ± 9, respectively) for each diet was included in the regression analysis. When the highest iron dose was excluded, linearity was achieved for all diets. As a result, statistical analysis was performed on the data minus the highest dose. Diet 6 contained the ferrous sulfate and was assigned a bioavailability of 100%. RBVs for FePO₄ sources 1–5 ranged from 51% to 99% (Table 2).

### Table 2. Percent RBVs and Solubility of Iron for the Five FePO₄ Sources.

| FePO₄ Source | %RBV ± SD | 0.02N HCl | 0.05N HCl | 0.1N HCl |
|--------------|-----------|-----------|-----------|----------|
| Source 1     |           |           |           |          |
| lot 1 (n = 1)| 99 ± 9 a  | 4.44      | 41.44     | 211.0    |
| lot 2 (n = 3)| -         | 8.13 ± 0.06| 49.43 ± 0.21| 179.0 ± 1.0 |
| Source 2     |           |           |           |          |
| lot 1 (n = 3)| 78 ± 7 b  | 0.65 ± 0.21| 1.36 ± 0.19| 2.88 ± 0.21 |
| Source 3     |           |           |           |          |
| lot 1 (n = 3)| 51 ± 5 d  | 0.12 ± 0.009| 0.23 ± 0.02| 0.29 ± 0.02 |
| lot 2 (n = 3)| -         | 0.16 ± 0.005| 0.23 ± 0.01| 0.40 ± 0.07 |
| lot 3 (n = 2)| -         | 0.10 ± 0.002| 0.15 ± 0.05| 0.33 ± 0.04 |
| Source 4     |           |           |           |          |
| lot 1 (n = 3)| 83 ± 7 b  | 1.28 ± 0.03| 4.20 ± 0.03| 10.09 ± 0.12 |
| Source 5     |           |           |           |          |
| lot 1 (n = 2)| 60 ± 6 c  | 0.10 (n = 1)| 0.10 ± 0.01| 0.23 ± 0.01 |

* Pooled variance: 8.588 13.676 176.982
* Pooled SD: 0.093 0.117 0.421
* Pooled assay CV: 5.00% 1.10% 0.88%

---

**3.2. In Vitro Solubility**

Solubility results for the iron sources are shown in Table 2. As the acidity of the solutions increased, the solubility of Source 1 increased approximately 50-fold while the solubility of Sources 2–5 increased from two to eight-fold. The iron in Source 1 (2 lots) was the most soluble in 0.1N HCl (18%–21%) followed by Source 4 (1 lot) (1.0%) >Source 2 (1 lot) (0.3%) >Source 3 (2 lots) and Source 5 (1 lot) (0.03%–0.04% and 0.02%, respectively). A regression analysis showed a statistically significant linear relationship between RBV and \( \log_{10} \) solubility (\( R^2 = 0.93, p = 0.008 \)).

**3.3. Particle Size and Surface Area**

Particle size (\( D_{10}, D_{50} \) and \( D_{90} \)) and surface area results are shown in Table 3. The \( D_{10} \) statistic measures the smallest particle size population present in a distribution. Data for this value found a significant difference only between Source 1 (10% of the distribution <1.9 ± 0.1 µm) and Source 5 (10% of the distribution <10.4 ± 0.0 µm) (\( p < 0.05 \)). The \( D_{50} \) or median particle size data grouped into three statistically different size distributions (\( p < 0.05 \)). Sources 3 and 5 had the highest number of large particles (median particle size 17.7 and 15.5 µm, respectively), followed by Source 1 (median particle size 9.3 µm), while Sources 2 and 4 had the highest number of small particles (median particle size 2 µm for both sources). \( D_{10} \) and \( D_{50} \) (median) particle size distribution data had the best, though poor,
inverse correlation to solubility of the particle size statistics ($R^2 = 0.38; p = 0.10$ and $R^2 = 0.59; p = 0.12$, respectively) and RBV ($R^2 = 0.67, p = 0.09$, and $R^2 = 0.44, p = 0.22$ respectively).

Table 3. Particle Size and Surface Area of FePO$_4$ sources $^a,b$.

| FePO$_4$ Sources | Mean | $D_{10}$ (µm) | Median $D_{50}$ (µm) | $D_{90}$ (µm) | Surface Area (m$^2$/g) |
|------------------|------|--------------|---------------------|--------------|-------------------------|
| Source 1         |      |              |                     |              |                         |
| lot 1            | $21.5 \pm 1.1$ | $1.9 \pm 0.1$ | $9.3 \pm 0.4$       | $59.0 \pm 2.1$ | $14.4 \pm 0.0$          |
| lot 2            | $20.4 \pm 1.2$ | $2.0 \pm 0.1$ | $9.2 \pm 0.6$       | $56.3 \pm 3.2$ | $15.3 \pm 0.1$          |
| Mean             | $21.0 \pm 1.2$ a | $1.9 \pm 0.1$ a | $9.3 \pm 0.4$ a | $57.6 \pm 2.9$ a | $14.9 \pm 0.44$ a       |
| Source 2         |      |              |                     |              |                         |
| lot 1            | $7.2 \pm 0.2$ | $0.9 \pm 0.1$ | $2.2 \pm 0.0$       | $22.0 \pm 0.9$ | $13.7 \pm 0.2$          |
| lot 2            | $4.0 \pm 0.4$ | $0.9 \pm 0.1$ | $1.8 \pm 0.0$       | $11.0 \pm 0.6$ | $17.6 \pm 0.3$          |
| Mean             | $5.6 \pm 1.6$ b | $0.9 \pm 0.1$ a,b | $2.0 \pm 0.2$ b | $16.5 \pm 5.8$ b | $15.6 \pm 2.0$ a,b      |
| Source 3         |      |              |                     |              |                         |
| lot 1            | $18.6 \pm 0.2$ | $8.2 \pm 0.2$ | $17.1 \pm 0.1$      | $31.9 \pm 0.4$ | $1.5 \pm 0.0$           |
| lot 2            | $20.4 \pm 0.1$ | $3.9 \pm 0.1$ | $19.4 \pm 0.1$      | $35.6 \pm 1.6$ | $1.1 \pm 0.0$           |
| lot 3            | $18.0 \pm 0.2$ | $5.4 \pm 0.3$ | $16.6 \pm 0.1$      | $32.5 \pm 0.3$ | $3.6 \pm 0.2$           |
| Mean             | $19.0 \pm 1.0$ a,c | $5.8 \pm 1.9$ a,b,c | $17.7 \pm 1.3$ c | $33.5 \pm 1.9$ b,c | $2.0 \pm 1.1$ c         |
| Source 4         |      |              |                     |              |                         |
| lot 1            | $5.4 \pm 0.2$ b | $0.8 \pm 0.0$ a,b,c | $2.0 \pm 0.0$ b | $15.9 \pm 0.9$ b,c,d | $11.0 \pm 0.1$ a,b       |
| Source 5         |      |              |                     |              |                         |
| lot 1            | $16.3 \pm 0.0$ a,c | $10.4 \pm 0.0$ b,c | $15.5 \pm 0.0$ c | $23.3 \pm 0.1$ b,c,d | $0.75 \pm 0.02$ c       |

$^a$ Values represent the mean ± SD of 6 measurements for particle size and surface area; $^b$ Means within a column without letters (a,b,c,d) in common are significantly different ($p < 0.05$).

Surface area measurements separated the five sources into two significantly different groups made up of Sources 3 and 5 and Sources 1, 2, and 4 ($p < 0.05$). As expected, the sources of FePO$_4$ with the largest particles (Sources 3 and 5) had the lowest surface areas ($2.0 \pm 1.1$ and $0.75 \pm 0.02$ m$^2$/g, respectively). Conversely, Sources 1, 2, and 4 were composed of smaller particles than Sources 3 and 5 and had higher surface areas ($14.9 \pm 0.44$, $15.6 \pm 2.0$, and $11.0 \pm 0.1$ m$^2$/g, respectively). A linear regression analysis of surface area versus RBV yielded an $R^2$ value of 0.83 ($p = 0.03$).

3.4. Amorphous Content

The microstructure of the FePO$_4$ sources was initially investigated using polarized light microscopy. The sources contained differing amounts of amorphous and crystalline material as shown in Figure 1.

Figure 1. Polarized light photomicrographs (360×) of the FePO$_4$ Sources 1–5 showing varying particle size distributions and amounts of crystalline and amorphous material. Highly structured crystalline regions are birefringent and appear brightly colored. Source 1 appears to be almost completely amorphous, containing only a trace of birefringent crystalline structure in some of the larger particles. Source 5 appears to be highly crystalline with most of the particles showing birefringence. Sources 2, 3, and 4 contain mixed amounts of amorphous and crystalline material, based on observations of birefringence.
The presence of amorphous material was confirmed qualitatively using X-ray diffraction. X-ray diffraction results are shown stacked for comparison (Figure 2). The X-ray diffraction patterns show that all the Sources, except for Source 1 that was amorphous, contained mixed amounts of amorphous and crystalline material.

![XRD Patterns for FePO4 Sources 1 (two lots), 2 (two lots) and 4 (one lot)](image1)

![XRD Patterns for FePO4 Sources 3 and 5 (two lots of each source)](image2)

**Figure 2.** The X-ray diffraction patterns for the five sources of FePO₄ are displayed from 2 to 50 degrees 2-Theta. The broad peak in the patterns located between 7 and 15 degrees 2 theta represents the amorphous component of the samples. The sharp peaks between 15 and 50 degrees represent crystalline material.

The amorphous contents of the samples were also estimated by comparison of moisture uptake by dynamic vapor sorption to the 100% amorphous standard (Table 4). The amorphous contents of Sources 1–5 varied from 1.7% to 23.8% (1% to 14.3% moisture uptake). Source 1 contained approximately 4–10-times the amorphous content of the other sources, depending on the lot tested. Source 2 and Source 4 had the next highest levels of amorphous material followed by Source 3, which
had slightly lower amounts. Source 5 had the lowest amorphous content of the samples tested. A linear regression analysis of log_{10} amorphous content versus RBV resulted in a $R^2 = 0.82; p = 0.033$.

Table 4. Amorphous Content of FePO$_4$ Sources.

| Source | Moisture Uptake a (%) | Amorphous Content (%) |
|--------|-----------------------|-----------------------|
| Source 1 |                        |                       |
| lot 1  | 14.3                  | 23.8                  |
| lot 2  | 9.3                   | 15.5                  |
| Source 2 |                        |                       |
| lot 1  | 3.2                   | 5.3                   |
| lot 2  | 3.9                   | 6.5                   |
| Source 3 |                        |                       |
| lot 1  | 1.8                   | 3.0                   |
| lot 2  | 1.0                   | 1.7                   |
| lot 3  | 2.5                   | 4.2                   |
| Source 4 |                        |                       |
| lot 1  | 3.4                   | 5.7                   |
| Source 5 |                        |                       |
| lot 1  | 1.2                   | 2.0                   |

a Moisture uptake is the mass increase due to moisture gain during DVS analysis.

4. Discussion

The FePO$_4$ sources analyzed in our study exhibited variable RBV consistent with the variability reported in the literature [3-6]. In two previous rat hemoglobin repletion studies, researchers also added FePO$_4$ to infant cereals and RTE breakfast cereals prior to processing. In the first, Rees and Monsen (1973) [9] added FePO$_4$ from a single source to a mixed grain infant cereal before cooking and drum drying that resulted in an RBV of 68%. In the second, Shah and coworkers (1979) [19] reported RBVs for two different FePO$_4$ fortified breakfast cereals of 33% and at 60%. The RBVs reported in these two studies (RBV 68% and 60%) were higher than typically reported in the literature (RBV 6%-46% (rat); 25%-32% (human)) and comparable to the lower end of the range of RBVs (51% to 99%) found in the current study [1,7]. Neither of these studies characterized the physical or chemical properties of the FePO$_4$ sources used making it difficult to draw conclusions about differences between the sources of FePO$_4$ and the factors influencing bioavailability.

In this research, the solubility of FePO$_4$ in 0.1N HCl was the parameter that correlated most highly with its bioavailability (log$_{10}$ solubility, $R^2 = 0.93, p = 0.008$). The log$_{10}$ transformation was used because of the very high solubility of Source 1 compared to the other sources. This finding is consistent with the SUSTAIN Task Force study in which the solubility of elemental iron in 0.1N HCl was also found to be highly predictive of its RBV ($R^2 = 0.86, p < 0.01$) [10]. Coccodrilli and coworkers (1976) [8] also found a positive relationship between the solubility of four commercial sources of FePO$_4$ in 10% HCl (5.8%-95.6%) and their corresponding RBV (4%-44%) in rat hemoglobin repletion studies (statistical correlation was not provided). An important determinant of solubility is the surface area of the particles. A linear regression of surface area data for FePO$_4$ versus log$_{10}$ solubility showed a positive relationship ($R^2 = 0.83; p = 0.002$). Decreasing particle size is often the approach taken to increase the surface area of materials; therefore, the particle size of poorly soluble forms of iron such as elemental iron [10], ferric pyrophosphate [20-22], and ferric/ferrous ammonium phosphate is decreased to increase dissolution rate [13,23]. In the SUSTAIN study, the surface area of elemental iron powders was also predictive of RBV ($R^2 = 0.81, p < 0.01$). Median ($D_{50}$) particle size of elemental iron had a significant inverse relationship to RBV but was less well correlated with RBV ($R^2 = 0.64, p < 0.01$) than surface area. The findings for elemental iron are consistent with the results for FePO$_4$ in this study in which the surface area of FePO$_4$ was a better predictor of RBV ($R^2 = 0.83; p = 0.03$) than
its median (D$_{50}$) particle size ($R^2 = 0.43, p = 0.22$) or D$_{10}$ particle size ($R^2 = 0.67, p = 0.09$). The weaker correlation of particle size versus surface area to RBV suggests that another factor is contributing to the solubility of FePO$_4$ and ultimately its bioavailability. Particle size measurements performed by light scattering and sieve techniques do not measure the internal porosity of particles and neither particle size nor surface area measurements characterize their crystalline structure.

Highly organized crystalline material can have varying degrees of molecular disorder, referred to as amorphous content, within its structure [24,25]. These amorphous regions are in a higher energy state and are more thermodynamically unstable than their crystalline counterparts; amorphous regions exhibit a higher absorption of water vapor that will result in increased solubility and reactivity [24]. FePO$_4$ is a semi-crystalline compound with varying degrees of molecular disorder within its particle structure, depending on its method of manufacture. Amorphous material can be formed during crystallization and subsequent processing and is often located on the particle surface increasing surface reactivity [24]. Amorphous FePO$_4$ has been shown to be an important determinant of bioavailability for plants and insects, and is hypothesized to be an important factor for its efficacy in humans [25]. Amorphous FePO$_4$ is extremely hydroscopic, which allows it to be quantified by DVS isotherms that measure the change in mass due to absorbed moisture, or moisture uptake. DVS analysis is a very sensitive technique that is commonly used in the pharmaceutical industry to measure the presence of small amounts of amorphous material in drug preparations [26,27]. It was applied in this research to quantify the amorphous content of FePO$_4$.

The amorphous content of the FePO$_4$ sources by DVS analysis ranged from 1.7% to 23.8%. Using the log$_{10}$ of both the amorphous content and solubility measurements, amorphous content was a better predictor of solubility ($R^2 = 0.91; p = 0.0002$) than median D$_{50}$ particle size ($R^2 = 0.59, p = 0.12$) and was highly correlated to RBV ($R^2 = 0.82; p = 0.03$). Source 1 had the highest RBV (99%), highest solubility in 0.1N HCl (19.5%, average of two lots), and highest amorphous content (23.8%) of the five sources tested. Sources 2 and 4 had intermediate RBV (78% and 83%, respectively), solubility in 0.1N HCl (0.3%, 1.0%, respectively) and amorphous contents (5.3% and 5.7%, respectively). Sources 3 and 5 had the lowest RBV (51% and 60%, respectively), solubility in 0.1N HCl <0.1%, and amorphous contents (3.0% and 2.0%, respectively). Several lots of FePO$_4$ were available from selected FePO$_4$ sources for analysis and there were modest differences in physiochemical properties from lot to lot, but these lot to lot differences did not overlap the source to source differences. The use of in vitro predictive physiochemical screening tests of various lots of FePO$_4$ from a single source would help assure consistent bioavailability.

Two previous bioavailability studies investigated the amorphous state of FePO$_4$ particles in addition to measuring its solubility in dilute HCl. In the first study, Hallberg and coworkers (1989) [13] prepared crystalline and amorphous FePO$_4$. The two forms of FePO$_4$ were added to flour that was baked into rolls and fed to human test subjects in a series of bioavailability studies. No analytical information was provided that characterized the amorphous or crystalline state of the FePO$_4$ particles or measured the amount of amorphous material present. Results showed that the amorphous FePO$_4$ had a higher RBV than crystalline FePO$_4$ (RBV 33% and 10%, respectively) and was over five-times more soluble (pH 1.0 HCl) than its crystalline counterpart [13]. In the second study, Rohner and coworkers (2007) [20] compared the relative bioavailability of a commercially available FePO$_4$ powder to two experimentally produced amorphous, nano-sized FePO$_4$ powders using the AOAC Rat Hemoglobin Repletion Bioassay. They measured the solubility of the sources (pH 1.0 HCl as compared to ferrous sulfate) and characterized the morphology and amorphous state by transmission electron microscopy/selected area electron diffraction, surface area by BET, and particle size by laser light scattering. The two nano-sized samples (median particle sizes of 30.5 and 10.7 nm) had solubility relative to ferrous sulfate of 79% and 85%, surface areas of 68.6 and 194.7 m$^2$/g, and RBV of 73% and 96%, respectively. [20]. Nano-sized materials are intentionally produced materials that have one or more dimensions ≤100 nm. Such materials have increased surface areas and can have chemical, physical, and biological properties that differ from those of their larger counterparts [28].
The commercial FePO₄ was made up of large, amorphous, and irregularly shaped porous particles that had 73% of the solubility of ferrous sulfate, a median particle size of 2.5 µm; surface area 32.6 m²/g; and RBV 61%. The authors noted that in addition to particle size, RBV may have been influenced by amorphous state and internal porosity contributing to high surface area (although these factors were not controlled as part of their study).

To the authors’ knowledge, this research is the first to use dynamic vapor sorption to quantify the amount of amorphous material contained in a range of well characterized, food-grade, commercial FePO₄ sources in which in vivo RBV was determined by the AOAC Rat Hemoglobin Repletion Bioassay using the same lots of FePO₄. The rat model is not the ideal predictor of bioavailability in humans since the physiology of iron absorption in rats is different than in humans. Rats are not as affected by substances in the diet that interfere with iron absorption such as phytic acid because rats in contrast to humans have the ability to produce phytase which degrades dietary sources of phytic acid [1,29–31]. Rats in contrast to humans are also able to synthesize ascorbic acid in their liver and secrete it into their gastric juice [32]. Ascorbic acid is known to increase the bioavailability of iron in foods [1,29,31,33]. RTE-cereals can be high in phytate, containing from 0.05% to 3.29%, depending on the type of grain and portion of the grain used. However, the phytate content of the RTE-cereal used to make the rat repletion diets was low (0.05%–0.09%) because it was made from corn grits which have had the germ and outer layers of the grain removed. These components of the corn kernel contain the highest amounts of phytate [30,34]. In addition, the RTE-cereal was fortified with 0.2 mg/g ascorbic acid that may have contributed to higher than expected RBVs. Although the rat hemoglobin repletion bioassay is not an ideal predictor of human bioavailability, it can provide accurate relative estimates of bioavailability when comparing different iron sources and samples within a single source.

Several researchers have compared the efficacy of the AOAC Rat Hemoglobin Repletion Bioassay with human bioavailability methods. Forbes and others (1989) [18] compared the human radioisotope extrinsic tag technique with the AOAC Rat Hemoglobin Repletion Bioassay. They concluded that the AOAC rat model was the economical method of choice for predicting relative bioavailability in humans. In the Sustain Task Force study, nine commercial elemental iron powders were evaluated by screening approaches to predict bioavailability in humans, including solubility in 0.1N HC and the AOAC Rat Hemoglobin Repletion Bioassay. The predicted RBVs were compared with the RBVs obtained from the human plasma iron tolerance test. The authors concluded that, “human plasma iron tolerance tests were in general agreement with the other measures of predicted bioavailability but they did not provide information that would have improved the precision of bioavailability estimates based on physical properties, dissolution in HCl and/or RBV in rats” [10].

Results of our research found that solubility gave the best prediction of RBV and is promising as an in vitro tool for predicting the bioavailability FePO₄. While solubility is highly predictive of RBV, solubility, in turn, is strongly linked to surface area and amorphous content. Amorphous FePO₄ was shown to be extremely hygroscopic by dynamic vapor sorption measurements, indicating it plays a key role in solubility. Dynamic vapor sorption is a sensitive technique to measure amorphous content and can potentially be used at a process control point to consistently produce FePO₄ with desirable bioavailability. The fortification of foods with iron requires balancing the benefits of using highly bioavailable iron with concerns for the pro-oxidant and negative organoleptic effects on product quality. RTE breakfast cereals are especially difficult to fortify with iron because their polyunsaturated lipid content makes them prone to oxidative rancidity, especially given the harsh cereal processing conditions such as pressure cooking, high shear milling, and extrusion processes. Highly soluble forms of iron such as ferrous sulfate and ferrous fumarate are unsuitable from a food quality perspective for many sensitive food applications; thus, affordable, nutritionally acceptable alternatives are needed. Based on 2016 market pricing and considering the iron content of the different iron sources, FePO₄ (29% iron) is three-times more expensive than ferrous sulfate heptahydrate (20% iron), 2.3-times more expensive than ferrous fumarate (32%), and about 1.5-times more expensive than food-grade ferric pyrophosphate (21% iron) [35]. Because data on the bioavailability of FePO₄ is limited, variable and
often poor, its use is not permitted in the European Union [36] and is limited elsewhere. This keeps production volumes low and increases the cost of this fortificant. Variable stability and organoleptic differences among the commercially available FePO$_4$ powders also limit its use. The distinct quality differences between the FePO$_4$ powders used in this research carried through to the RTE-cereal. The rat diets made with the poorest FePO$_4$ source from an organoleptic point of view had the highest solubility, amorphous content, and RBV of the sources in the study. This was true of the other FePO$_4$ sources in which product quality decreased as solubility, amorphous content and RBV increased. Cereals made with Source 1 (and ferrous sulfate) in particular had gray-green discoloration and a metallic off-flavor. Fortification with Source 5 resulted in excellent quality product without defects.

In conclusion, it is possible to select FePO$_4$ sources with acceptable to good organoleptic properties that have consistent and desirable RBV in RTE-cereal applications. Future research is needed to further investigate the relationship between amorphous content and the bioavailability of FePO$_4$ powders with amorphous contents between 5% and 25%. Dynamic vapor sorption has potential as a new screening tool to measure amorphous content in FePO$_4$ powders to predict solubility and produce powders with consistent RBV and satisfactory organoleptic properties.

Acknowledgments: The authors wish to thank the following people for their expert consultation and laboratory resources: Daryl Williams and Jerry Heng, Department of Engineering, Imperial College, London, UK for DVS analysis; Jeff Stassi and Mike Rankin, Covance Laboratories, Madison, WI, USA for iron solubility analysis; Richard Karuhn and William Kopesky at Particle Technology Labs, Ltd., Downers Grove, IL, USA for particle size distribution and surface area analyses; Mark A. Bukantis, McCrone Associates, Inc., Westmont, IL, USA for X-ray diffraction; and Wayne J. Genck, Genck International, Park Forest, IL, USA for microstructure analysis. Statistical guidance was provided by Tony Gualtieri and Roy Robertson, Kellogg Company, Battle Creek, MI, USA.

Author Contributions: Author Robin S. Dickmann, Gale M. Strasburg, and Dale R. Romsos designed the study and participated in the analysis, interpretation of the results, and preparation of the manuscript. Authors Grace H. Lai and Hsimin Huang provided crystallography and analytical expertise and participated in the interpretation of results. Author Lori A. Wilson provided cereal processing expertise, produced the experimental samples, and participated in interpretation of results. All authors read and approved the final manuscript.

Conflicts of Interest: Authors declare that funding for this research was provided by the Kellogg Company, Battle Creek, MI, USA. The Kellogg Company is a multinational manufacturer and marketer of ready-to-eat cereal and convenience foods. The corresponding author is a former employee and three of the authors are current or retired employees of the Kellogg Company.

References
1. Hurrell, R.F. How to Ensure Adequate Iron Absorption from Iron-Fortified Food. *Nutr. Rev.* 2002, 60, S7–S15. [CrossRef] [PubMed]
2. Turner, L. Monterey workshop summary: Evaluating the usefulness of elemental iron powders. *Nutr. Rev.* 2002, 60, S16–S17. [CrossRef] [PubMed]
3. Ranum, P.; Lynch, S.; Bothwell, T.; Hallberg, L.; Hurrell, R.; Whittaker, P.; Rosado, J.L.; Davidsson, L.; Mannar, V.; Walter, T.; *et al.* Guidelines for Iron Fortification of Cereal Food Staples. May 2001; SUSTAIN web site. Micronutrient Fortification. Available online: http://www.sustaintech.org/technology/iron.htm (accessed on 1 November 2015).
4. Wienk, K.J.H.; Marx, J.J.; Beynen, A.C. The concept of iron bioavailability and its assessment. *Eur. J. Nutr.* 1999, 38, 51–75. [CrossRef] [PubMed]
5. Hurrell, R.; Bothwell, T.; Cook, J.D.; Davidsson, L.; Fairweather-Tait, S.; Hallberg, L.; Lynch, S.; Rosado, J.; Walter, T.; Whittaker, P. The usefulness of elemental iron for cereal flour fortification: A SUSTAIN Task Force report. *Nutr. Rev.* 2002, 60, 391–406. [CrossRef] [PubMed]
6. Shah, B.G.; Giroux, A.; Befonjie, B. Specifications for reduced iron as a food additive. *J. Agric. Food Chem.* 1979, 25, 592–594. [CrossRef]
7. Hurrell, R.F. Fortification: Overcoming Technical and Practical Barriers. *J. Nutr.* 2002, 132, 806S–812S. [PubMed]
8. Coccodrilli, G.D.; Reussner, G.H.; Thiessen, R. Relative Biological Values of iron Supplements in Processed Food Products. *J. Agric. Food Chem.* 1976, 24, 351–353. [CrossRef] [PubMed]
9. Rees, J.; Monsen, E. Absorption of fortification iron by the rat: Comparison of type and level of iron incorporated into mixed grain cereal. *J. Agric. Food Chem.* 1973, 21, 913–915. [CrossRef] [PubMed]

10. Lynch, S.R.; Bothwell, T.; Campbell, L.; Cowan, K.; Halberg, L.; Hoppe, M.; Hultthen, L.; Hunt, J.R.; Hurrell, R.F.; Miller, D.; et al. A comparison of the physical properties, screening procedures and a human efficacy trial for predicting the bioavailability of commercial elemental iron powders used for food fortification. *Int. J. Vitam. Nutr. Res.* 2007, 77, 107–124. [CrossRef] [PubMed]

11. Swain, J.H.; Newman, S.M.; Hunt, J.R. Bioavailability of elemental iron powders to rats is less than bakery grade ferrous sulfate and predicted by iron solubility and particle surface area. *J. Nutr.* 2003, 133, 3546–3552. [PubMed]

12. Food Fortification Initiative. Enhancing Grains for Healthier Lives Web Site. Available online: http://www.ffinetwork.org/plan/standards.html (accessed on 1 November 2015).

13. Hallberg, L.; Rossander-Hulthen, L.; Gramatkovski, E. Iron fortification of flour with a complex ferric orthophosphate. *Am. J. Clin. Nutr.* 1989, 50, 129–133. [PubMed]

14. Nalubola, R.; Nestel, P. Manual for Wheat Flour Fortification with Iron. Part 2. Technical and Operational Guidelines. Oct. 2000; USAID Micronutrient Program MOST Publications Web Site. Available online: http://www.a2zproject.org/~a2zorg/node/103 (accessed on 1 November 2015).

15. Mintel Global New Products Database (GNPD) Web Site. Available online: http://www.gnpd.com (accessed on 1 November 2015).

16. Official Methods of Analysis of AOAC International. *Bioavailability of Iron: Rat Hemoglobin Repletion Bioassay*, 16th ed.; Method 974.31; AOAC International: Gaithersburg, MD, USA, 1974.

17. Official methods of Analysis of AOAC International. *Elements by ICP Mass Spectrometry*, 18th ed.; Method 993.14; AOAC International: Gaithersburg, MD, USA, 2005.

18. Forbes, A.L.; Adams, C.E.; Arnaud, M.J.; Chichester, C.O.; Cook, J.D.; Harrison, B.N.; Hurrell, R.F.; Kaem, S.G.; Morris, E.R.; Tanner, J.T.; et al. Comparison of in vitro, animal, and clinical determinations of iron bioavailability: International nutritional anemia consultative group task force report. *Am. J. Clin. Nutr.* 1989, 49, 225–238. [PubMed]

19. Shah, B.G.; Giroux, A.; Belonje, B. Bioavailability of iron from iron phosphates in cereals and infant foods. *J. Agric. Food Chem.* 1979, 27, 845–847. [CrossRef] [PubMed]

20. Rohner, F.; Ernst, F.O.; Arnold, M.; Hilbe, M.; Biebingger, R.; Ehrensperger, F.; Pratsinio, S.E.; Langhans, W.; Hurrell, R.F.; Zimmermann, M.B. Synthesis, characterization and bioavailability in rats of ferric phosphate nanoparticles. *J. Nutr.* 2007, 137, 164–619.

21. Fidler, M.C.; Davidsson, L.; Zeder, C.; Walczyk, T.; Marti, I.; Hurrell, R.F. Effect of ascorbic acid and particle size on iron absorption from ferric pyrophosphate in adult women. *Int. J. Vitam. Nutr. Res.* 2004, 74, 294–300. [CrossRef] [PubMed]

22. Fidler, M.C.; Walczyk, T.; Davidsson, L.; Zeder, C.; Sakaguchi, N.; Juneje, L.R.; Hurrell, R.F. A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. *Br. J. Nutr.* 2004, 91, 107–112. [CrossRef] [PubMed]

23. Walczyk, T.; Kastenmayer, P.; Storcksdieck Genannt Bonsmann, S.; Zeder, C; Grathwohl, D.; Hurrell, R.F. Ferrous ammonium phosphate (FeNH4PO4) as a new food fortificant: Iron bioavailability compared to ferrous sulfate and ferric pyrophosphate from an instant milk drink. *Eur. J. Nutr.* 2013, 52, 1361–1368. [CrossRef] [PubMed]

24. Buckton, G.; Darcy, P. Assessment of disorder in crystalline powders—A review of the analytical techniques and their application. *Int. J. Pharm.* 1999, 179, 141–158. [CrossRef]

25. Willis, R.B.; Allen, P.R. Measurement of amorphous ferric phosphate to assess iron bioavailability in diets and diet ingredients. *Analyst* 1999, 124, 425–430. [CrossRef]

26. Mackin, L.; Zanon, R.; Park, J.M.; Foster, K.; Opalenik, H.; Demonte. M. Quantification of low levels (<10%) of amorphous content in micronized active batches using dynamic vapor sorption and thermal microcalorimetry. *Int. J. Pharm.* 2002, 231, 227–236. [PubMed]

27. Burnett, D.; Malde, N.; Williams, D. Characterizing amorphous materials with gravimetric vapour sorption techniques. *Pharm. Technol. Eur.* 2009, 21, 41–45.

28. Science and Research Topics: Nanotechnology. FDA Web Site. Available online: http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/default.htm (accessed on 1 November 2015).
29. Lynch, S.R. Food Iron Absorption and Its Importance for the Design of Food Fortification Strategies. *Nutr. Rev.* 2002, 60, S3–S6. [CrossRef] [PubMed]

30. Reddy, N.R.; Pierson, M.D.; Sathe, S.K.; Salunkhe, D.K. *Phytates in Cereals and Legumes*; CRC Press Taylor & Francis Group: Boca Raton, FL, USA, 1989; Chapter 8, pp. 71–76.

31. Moretti, D.; Zimmermann, M.B.; Wegmuller, R.; Walczyk, T.; Zeder, C.; Hurrell, R.F. Iron status and food matrix strongly affect the relative bioavailability of ferric pyrophosphate in humans. *Am. J. Clin. Nutr.* 2006, 83, 632–638. [PubMed]

32. Muto, N.; Ohta, T.; Suzuki, T.; Itoh, N.; Tanaka, K. Evidence for the involvement of a muscarinic receptor in ascorbic acid secretion in the rat stomach. *Biochem. Pharmacol.* 1997, 53, 553–559. [CrossRef]

33. Hallberg, L. Iron and vitamins. *Bibl. Nutr. Dieta* 1995, 52, 20–29. [PubMed]

34. Reddy, N.R. Occurrence, Distribution, Content and Dietary Intake of Phytate. In *Food Phytates*; Reddy, N.R., Sathe, S.K., Eds.; CRC Press Taylor & Francis Group: Boca Raton, FL, USA, 2001; Chapter 3, pp. 25–44.

35. Dr. Paul Lohmann GmbH KG. Personal Communication, Food/Animal Nutrition. Web Site. Available online: http://www.lohmann4minerals.com (accessed on 1 November 2015).

36. Commission Regulation (EC) Directive 2002/46/EC of the European Parliament and of Council and Regulation, Annex II. European Commission on Food Supplements Web Site. Available online: http://ec.europa.eu/food/safety/labelling_nutrition/supplements/index_en.htm (accessed on 1 November 2015).

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).